Gilead to Stop Phase 3 Study 116 of Idelalisib in Chronic Lymphocytic Leukemia ... Wall Street Journal This DMC recommendation is based on a predefined interim analysis showing highly statistically significant efficacy for the primary endpoint of progression-free survival in patients receiving idelalisib plus rituximab compared to those receiving ... |
